APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastric Carcinomas Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gastric Carcinomas Drugs Market Analysis and Forecast 2026-2032

2 January 2026195 pages

Choose your research edition.

Industry ResearchGastric Carcinomas Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastric Carcinomas Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Gastric Carcinomas Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastric Carcinomas Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastric Carcinomas Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Gastric Carcinomas Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gastric Carcinomas Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gastric Carcinomas Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gastric Carcinomas Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gastric Carcinomas Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gastric Carcinomas Drugs include Chiatai Tianqing, Fujian Haiwang Fuyao Pharmacy Limited Company, Merck & Co, Novo Nordisk, Taiho Pharmaceutical, Bayer, Jiangsu Hengrui Medicine Company Limited, Pfizer and Eli Lilly and Company, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gastric Carcinomas Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gastric Carcinomas Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Gastric Carcinomas Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gastric Carcinomas Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gastric Carcinomas Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gastric Carcinomas Drugs revenue, projected growth trends, production technology, application and end-user industry.

Gastric Carcinomas Drugs Segment by Company

Chiatai Tianqing

Fujian Haiwang Fuyao Pharmacy Limited Company

Merck & Co

Novo Nordisk

Taiho Pharmaceutical

Bayer

Jiangsu Hengrui Medicine Company Limited

Pfizer

Eli Lilly and Company

Roche

Qilu Pharma

Shandong New Era Hotel Pharmaceutical Industry Limited Company

Gastric Carcinomas Drugs Segment by Type

First Line Treatment

Second Line Treatment

Three Line Treatment

Gastric Carcinomas Drugs Segment by Application

Hospital

Clinic

Others

Gastric Carcinomas Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Carcinomas Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastric Carcinomas Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Carcinomas Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gastric Carcinomas Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gastric Carcinomas Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gastric Carcinomas Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gastric Carcinomas Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. First Line Treatment Major Player Table 3. Second Line Treatment Major Player Table 4. Three Line Treatment Major Player Table 5. Global Gastric Carcinomas Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Clinic Major Player Table 8. Others Major Player Table 9. Gastric Carcinomas Drugs Industry Trends Table 10. Gastric Carcinomas Drugs Industry Drivers Table 11. Gastric Carcinomas Drugs Industry Opportunities and Challenges Table 12. Gastric Carcinomas Drugs Industry Restraints Table 13. Global Gastric Carcinomas Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Gastric Carcinomas Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Gastric Carcinomas Drugs Market Share by Region (2021-2026) Table 16. Global Gastric Carcinomas Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Gastric Carcinomas Drugs Market Share by Region (2027-2032) Table 18. Global Gastric Carcinomas Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Gastric Carcinomas Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Gastric Carcinomas Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Gastric Carcinomas Drugs Key Players Headquarters & Area Served Table 22. Global Gastric Carcinomas Drugs Players, Product Type & Application Table 23. Global Gastric Carcinomas Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Gastric Carcinomas Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Gastric Carcinomas Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gastric Carcinomas Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Gastric Carcinomas Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Gastric Carcinomas Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Gastric Carcinomas Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Gastric Carcinomas Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gastric Carcinomas Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Gastric Carcinomas Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Gastric Carcinomas Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Gastric Carcinomas Drugs Revenue Market Share by Application (2027-2032) Table 36. Chiatai Tianqing Company Information Table 37. Chiatai Tianqing Business Overview Table 38. Chiatai Tianqing Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Chiatai Tianqing Gastric Carcinomas Drugs Product Portfolio Table 40. Chiatai Tianqing Recent Development Table 41. Fujian Haiwang Fuyao Pharmacy Limited Company Company Information Table 42. Fujian Haiwang Fuyao Pharmacy Limited Company Business Overview Table 43. Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Product Portfolio Table 45. Fujian Haiwang Fuyao Pharmacy Limited Company Recent Development Table 46. Merck & Co Company Information Table 47. Merck & Co Business Overview Table 48. Merck & Co Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Merck & Co Gastric Carcinomas Drugs Product Portfolio Table 50. Merck & Co Recent Development Table 51. Novo Nordisk Company Information Table 52. Novo Nordisk Business Overview Table 53. Novo Nordisk Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Novo Nordisk Gastric Carcinomas Drugs Product Portfolio Table 55. Novo Nordisk Recent Development Table 56. Taiho Pharmaceutical Company Information Table 57. Taiho Pharmaceutical Business Overview Table 58. Taiho Pharmaceutical Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Taiho Pharmaceutical Gastric Carcinomas Drugs Product Portfolio Table 60. Taiho Pharmaceutical Recent Development Table 61. Bayer Company Information Table 62. Bayer Business Overview Table 63. Bayer Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Bayer Gastric Carcinomas Drugs Product Portfolio Table 65. Bayer Recent Development Table 66. Jiangsu Hengrui Medicine Company Limited Company Information Table 67. Jiangsu Hengrui Medicine Company Limited Business Overview Table 68. Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Product Portfolio Table 70. Jiangsu Hengrui Medicine Company Limited Recent Development Table 71. Pfizer Company Information Table 72. Pfizer Business Overview Table 73. Pfizer Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Pfizer Gastric Carcinomas Drugs Product Portfolio Table 75. Pfizer Recent Development Table 76. Eli Lilly and Company Company Information Table 77. Eli Lilly and Company Business Overview Table 78. Eli Lilly and Company Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Eli Lilly and Company Gastric Carcinomas Drugs Product Portfolio Table 80. Eli Lilly and Company Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Gastric Carcinomas Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Roche Gastric Carcinomas Drugs Product Portfolio Table 85. Roche Recent Development Table 86. Qilu Pharma Company Information Table 87. Qilu Pharma Business Overview Table 88. Qilu Pharma Gastric Carcinomas Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Qilu Pharma Gastric Carcinomas Drugs Product Portfolio Table 90. Qilu Pharma Recent Development Table 91. Shandong New Era Hotel Pharmaceutical Industry Limited Company Company Information Table 92. Shandong New Era Hotel Pharmaceutical Industry Limited Company Business Overview Table 93. Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Product Portfolio Table 95. Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Development Table 96. North America Gastric Carcinomas Drugs Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Gastric Carcinomas Drugs Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Gastric Carcinomas Drugs Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Gastric Carcinomas Drugs Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Gastric Carcinomas Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Gastric Carcinomas Drugs Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Gastric Carcinomas Drugs Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Gastric Carcinomas Drugs Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Gastric Carcinomas Drugs Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Gastric Carcinomas Drugs Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Gastric Carcinomas Drugs Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Gastric Carcinomas Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Gastric Carcinomas Drugs Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Gastric Carcinomas Drugs Revenue by Country (US$ Million) & (2027-2032) Table 110. China Gastric Carcinomas Drugs Revenue by Type (2021-2026) & (US$ Million) Table 111. China Gastric Carcinomas Drugs Revenue by Type (2027-2032) & (US$ Million) Table 112. China Gastric Carcinomas Drugs Revenue by Application (2021-2026) & (US$ Million) Table 113. China Gastric Carcinomas Drugs Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Gastric Carcinomas Drugs Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Gastric Carcinomas Drugs Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Gastric Carcinomas Drugs Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Gastric Carcinomas Drugs Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Gastric Carcinomas Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Gastric Carcinomas Drugs Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Gastric Carcinomas Drugs Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Gastric Carcinomas Drugs Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Gastric Carcinomas Drugs Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Gastric Carcinomas Drugs Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Gastric Carcinomas Drugs Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Gastric Carcinomas Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Gastric Carcinomas Drugs Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Gastric Carcinomas Drugs Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Gastric Carcinomas Drugs Image Figure 2. Global Gastric Carcinomas Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastric Carcinomas Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. First Line Treatment Image Figure 5. Second Line Treatment Image Figure 6. Three Line Treatment Image Figure 7. Global Gastric Carcinomas Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Gastric Carcinomas Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinic Image Figure 11. Others Image Figure 12. Global Gastric Carcinomas Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Gastric Carcinomas Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Gastric Carcinomas Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Gastric Carcinomas Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Gastric Carcinomas Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gastric Carcinomas Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Gastric Carcinomas Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Gastric Carcinomas Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Gastric Carcinomas Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Gastric Carcinomas Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Gastric Carcinomas Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Gastric Carcinomas Drugs Revenue Share by Type (2021-2032) Figure 25. North America Gastric Carcinomas Drugs Revenue Share by Application (2021-2032) Figure 26. North America Gastric Carcinomas Drugs Revenue Share by Country (2021-2032) Figure 27. United States Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Gastric Carcinomas Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Gastric Carcinomas Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Gastric Carcinomas Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Gastric Carcinomas Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Gastric Carcinomas Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Gastric Carcinomas Drugs Revenue Share by Type (2021-2032) Figure 44. China Gastric Carcinomas Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Gastric Carcinomas Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Gastric Carcinomas Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Gastric Carcinomas Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Gastric Carcinomas Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Gastric Carcinomas Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Gastric Carcinomas Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Gastric Carcinomas Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Gastric Carcinomas Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Gastric Carcinomas Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • First Line Treatment
  • Second Line Treatment
  • Three Line Treatment
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chiatai Tianqing
  • Fujian Haiwang Fuyao Pharmacy Limited Company
  • Merck & Co
  • Novo Nordisk
  • Taiho Pharmaceutical
  • Bayer
  • Jiangsu Hengrui Medicine Company Limited
  • Pfizer
  • Eli Lilly and Company
  • Roche
  • Qilu Pharma
  • Shandong New Era Hotel Pharmaceutical Industry Limited Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gastric Carcinomas Drugs Market by Type
  3. 1.2.1 Global Gastric Carcinomas Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 First Line Treatment
  5. 1.2.3 Second Line Treatment
  6. 1.2.4 Three Line Treatment
  7. 1.3 Gastric Carcinomas Drugs Market by Application
  8. 1.3.1 Global Gastric Carcinomas Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinic
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Gastric Carcinomas Drugs Market Dynamics
  1. 2.1 Gastric Carcinomas Drugs Industry Trends
  2. 2.2 Gastric Carcinomas Drugs Industry Drivers
  3. 2.3 Gastric Carcinomas Drugs Industry Opportunities and Challenges
  4. 2.4 Gastric Carcinomas Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gastric Carcinomas Drugs Market Perspective (2021-2032)
  2. 3.2 Global Gastric Carcinomas Drugs Growth Trends by Region
  3. 3.2.1 Global Gastric Carcinomas Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gastric Carcinomas Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Gastric Carcinomas Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gastric Carcinomas Drugs Revenue by Players
  2. 4.1.1 Global Gastric Carcinomas Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Gastric Carcinomas Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gastric Carcinomas Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gastric Carcinomas Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gastric Carcinomas Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Gastric Carcinomas Drugs Players, Product Type & Application
  8. 4.5 Global Gastric Carcinomas Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gastric Carcinomas Drugs Market CR5 and HHI
  11. 4.6.3 2025 Gastric Carcinomas Drugs Tier 1, Tier 2, and Tier 3
5 Gastric Carcinomas Drugs Market Size by Type
  1. 5.1 Global Gastric Carcinomas Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gastric Carcinomas Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Gastric Carcinomas Drugs Revenue Market Share by Type (2021-2032)
6 Gastric Carcinomas Drugs Market Size by Application
  1. 6.1 Global Gastric Carcinomas Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gastric Carcinomas Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Gastric Carcinomas Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Chiatai Tianqing
  2. 7.1.1 Chiatai Tianqing Company Information
  3. 7.1.2 Chiatai Tianqing Business Overview
  4. 7.1.3 Chiatai Tianqing Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Chiatai Tianqing Gastric Carcinomas Drugs Product Portfolio
  6. 7.1.5 Chiatai Tianqing Recent Developments
  7. 7.2 Fujian Haiwang Fuyao Pharmacy Limited Company
  8. 7.2.1 Fujian Haiwang Fuyao Pharmacy Limited Company Company Information
  9. 7.2.2 Fujian Haiwang Fuyao Pharmacy Limited Company Business Overview
  10. 7.2.3 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Fujian Haiwang Fuyao Pharmacy Limited Company Gastric Carcinomas Drugs Product Portfolio
  12. 7.2.5 Fujian Haiwang Fuyao Pharmacy Limited Company Recent Developments
  13. 7.3 Merck & Co
  14. 7.3.1 Merck & Co Company Information
  15. 7.3.2 Merck & Co Business Overview
  16. 7.3.3 Merck & Co Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co Gastric Carcinomas Drugs Product Portfolio
  18. 7.3.5 Merck & Co Recent Developments
  19. 7.4 Novo Nordisk
  20. 7.4.1 Novo Nordisk Company Information
  21. 7.4.2 Novo Nordisk Business Overview
  22. 7.4.3 Novo Nordisk Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novo Nordisk Gastric Carcinomas Drugs Product Portfolio
  24. 7.4.5 Novo Nordisk Recent Developments
  25. 7.5 Taiho Pharmaceutical
  26. 7.5.1 Taiho Pharmaceutical Company Information
  27. 7.5.2 Taiho Pharmaceutical Business Overview
  28. 7.5.3 Taiho Pharmaceutical Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Taiho Pharmaceutical Gastric Carcinomas Drugs Product Portfolio
  30. 7.5.5 Taiho Pharmaceutical Recent Developments
  31. 7.6 Bayer
  32. 7.6.1 Bayer Company Information
  33. 7.6.2 Bayer Business Overview
  34. 7.6.3 Bayer Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Bayer Gastric Carcinomas Drugs Product Portfolio
  36. 7.6.5 Bayer Recent Developments
  37. 7.7 Jiangsu Hengrui Medicine Company Limited
  38. 7.7.1 Jiangsu Hengrui Medicine Company Limited Company Information
  39. 7.7.2 Jiangsu Hengrui Medicine Company Limited Business Overview
  40. 7.7.3 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Jiangsu Hengrui Medicine Company Limited Gastric Carcinomas Drugs Product Portfolio
  42. 7.7.5 Jiangsu Hengrui Medicine Company Limited Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Gastric Carcinomas Drugs Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Eli Lilly and Company
  50. 7.9.1 Eli Lilly and Company Company Information
  51. 7.9.2 Eli Lilly and Company Business Overview
  52. 7.9.3 Eli Lilly and Company Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Eli Lilly and Company Gastric Carcinomas Drugs Product Portfolio
  54. 7.9.5 Eli Lilly and Company Recent Developments
  55. 7.10 Roche
  56. 7.10.1 Roche Company Information
  57. 7.10.2 Roche Business Overview
  58. 7.10.3 Roche Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Roche Gastric Carcinomas Drugs Product Portfolio
  60. 7.10.5 Roche Recent Developments
  61. 7.11 Qilu Pharma
  62. 7.11.1 Qilu Pharma Company Information
  63. 7.11.2 Qilu Pharma Business Overview
  64. 7.11.3 Qilu Pharma Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Qilu Pharma Gastric Carcinomas Drugs Product Portfolio
  66. 7.11.5 Qilu Pharma Recent Developments
  67. 7.12 Shandong New Era Hotel Pharmaceutical Industry Limited Company
  68. 7.12.1 Shandong New Era Hotel Pharmaceutical Industry Limited Company Company Information
  69. 7.12.2 Shandong New Era Hotel Pharmaceutical Industry Limited Company Business Overview
  70. 7.12.3 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Shandong New Era Hotel Pharmaceutical Industry Limited Company Gastric Carcinomas Drugs Product Portfolio
  72. 7.12.5 Shandong New Era Hotel Pharmaceutical Industry Limited Company Recent Developments
8 North America
  1. 8.1 North America Gastric Carcinomas Drugs Revenue (2021-2032)
  2. 8.2 North America Gastric Carcinomas Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Gastric Carcinomas Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Gastric Carcinomas Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Gastric Carcinomas Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Gastric Carcinomas Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Gastric Carcinomas Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Gastric Carcinomas Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Gastric Carcinomas Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Gastric Carcinomas Drugs Revenue by Country
  11. 8.6.1 North America Gastric Carcinomas Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gastric Carcinomas Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Gastric Carcinomas Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Gastric Carcinomas Drugs Revenue (2021-2032)
  2. 9.2 Europe Gastric Carcinomas Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gastric Carcinomas Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gastric Carcinomas Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Gastric Carcinomas Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gastric Carcinomas Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gastric Carcinomas Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gastric Carcinomas Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Gastric Carcinomas Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gastric Carcinomas Drugs Revenue by Country
  11. 9.6.1 Europe Gastric Carcinomas Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gastric Carcinomas Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gastric Carcinomas Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Gastric Carcinomas Drugs Revenue (2021-2032)
  2. 10.2 China Gastric Carcinomas Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Gastric Carcinomas Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Gastric Carcinomas Drugs Revenue by Type (2027-2032)
  5. 10.3 China Gastric Carcinomas Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Gastric Carcinomas Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Gastric Carcinomas Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Gastric Carcinomas Drugs Revenue by Application (2027-2032)
  9. 10.5 China Gastric Carcinomas Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gastric Carcinomas Drugs Revenue (2021-2032)
  2. 11.2 Asia Gastric Carcinomas Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gastric Carcinomas Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gastric Carcinomas Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Gastric Carcinomas Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gastric Carcinomas Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gastric Carcinomas Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gastric Carcinomas Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Gastric Carcinomas Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gastric Carcinomas Drugs Revenue by Country
  11. 11.6.1 Asia Gastric Carcinomas Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gastric Carcinomas Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gastric Carcinomas Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gastric Carcinomas Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Gastric Carcinomas Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gastric Carcinomas Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gastric Carcinomas Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gastric Carcinomas Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gastric Carcinomas Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gastric Carcinomas Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gastric Carcinomas Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gastric Carcinomas Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gastric Carcinomas Drugs Revenue by Country
  11. 12.6.1 SAMEA Gastric Carcinomas Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gastric Carcinomas Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gastric Carcinomas Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst